Highly Sensitive Detection and Molecular Subtyping of Breast Cancer Cells Using Machine Learning-assisted SERS Technology

Q3 Engineering
Xinyu Miao, Lei Xu, Li Xian Sun, Yujiao Xie, Jiahao Zhang, Xiawei Xu, Yue Hu, Zhouxu Zhang, Aochi Liu, Zhiwei Hou, Aiguo Wu, Jie Lin
{"title":"Highly Sensitive Detection and Molecular Subtyping of Breast Cancer Cells Using Machine Learning-assisted SERS Technology","authors":"Xinyu Miao, Lei Xu, Li Xian Sun, Yujiao Xie, Jiahao Zhang, Xiawei Xu, Yue Hu, Zhouxu Zhang, Aochi Liu, Zhiwei Hou, Aiguo Wu, Jie Lin","doi":"10.26599/nbe.2025.9290113","DOIUrl":null,"url":null,"abstract":"Breast cancer has always been a research hotspot in the medical field due to its highest incidence and mortality rates among women worldwide. However, the significant molecular heterogeneity of breast cancer presents major challenges for its diagnosis and treatment. Surface-enhanced Raman spectroscopy (SERS) has gained considerable attention for its capability in trace detection and molecular analysis. To accurately identify different breast cancer cell subtypes, constructing reliable SERS bioprobes is essential. Therefore, a specific highly expressed receptor, human epidermal growth factor receptor 2 (HER-2), was employed to explore SERS bioprobes in this study. Two bioprobes capable of targeting breast cancer cells, Au NPs@4-MBA@PDA@aHER-2 and Au NPs@4-MPY@PDA@aHER-2, were synthesized. SERS performance testing indicated that the Au NPs were able to detect and trace molecules at concentrations as low as 2 × 10<sup>–9</sup> mol/L. Additionally, the two bioprobes exhibited good spectral stability with a relative standard deviation (RSD) of 9.58%. Moreover, by constructing a “symphonic SERS spectra” of the two bioprobes with prominent component analysis-linear discriminant analysis (PCA-LDA), the classification accuracy of distinguishing white blood cells (WBCs) and two breast cancer cell subtypes (SK-BR-3 and MDA-MB-231) reached up to 97.33%. The integration of machine learning with SERS detection provides a novel technological pathway for the early diagnosis and personalized treatment of breast cancer.","PeriodicalId":18971,"journal":{"name":"Nano Biomedicine and Engineering","volume":"17 1","pages":"129-142"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciopen.com/local/article_pdf/10.26599/NBE.2025.9290113.pdf","citationCount":"27","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nano Biomedicine and Engineering","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.26599/nbe.2025.9290113","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Engineering","Score":null,"Total":0}
引用次数: 27

Abstract

Breast cancer has always been a research hotspot in the medical field due to its highest incidence and mortality rates among women worldwide. However, the significant molecular heterogeneity of breast cancer presents major challenges for its diagnosis and treatment. Surface-enhanced Raman spectroscopy (SERS) has gained considerable attention for its capability in trace detection and molecular analysis. To accurately identify different breast cancer cell subtypes, constructing reliable SERS bioprobes is essential. Therefore, a specific highly expressed receptor, human epidermal growth factor receptor 2 (HER-2), was employed to explore SERS bioprobes in this study. Two bioprobes capable of targeting breast cancer cells, Au NPs@4-MBA@PDA@aHER-2 and Au NPs@4-MPY@PDA@aHER-2, were synthesized. SERS performance testing indicated that the Au NPs were able to detect and trace molecules at concentrations as low as 2 × 10–9 mol/L. Additionally, the two bioprobes exhibited good spectral stability with a relative standard deviation (RSD) of 9.58%. Moreover, by constructing a “symphonic SERS spectra” of the two bioprobes with prominent component analysis-linear discriminant analysis (PCA-LDA), the classification accuracy of distinguishing white blood cells (WBCs) and two breast cancer cell subtypes (SK-BR-3 and MDA-MB-231) reached up to 97.33%. The integration of machine learning with SERS detection provides a novel technological pathway for the early diagnosis and personalized treatment of breast cancer.
利用机器学习辅助SERS技术对乳腺癌细胞进行高灵敏度检测和分子分型
乳腺癌是世界范围内女性发病率和死亡率最高的疾病,一直是医学领域的研究热点。然而,乳腺癌显著的分子异质性为其诊断和治疗带来了重大挑战。表面增强拉曼光谱(SERS)因其在痕量检测和分子分析方面的优势而受到广泛关注。为了准确地识别不同的乳腺癌细胞亚型,构建可靠的SERS生物探针是必不可少的。因此,本研究采用特异性高表达受体——人表皮生长因子受体2 (HER-2)来探索SERS生物探针。合成了两种能够靶向乳腺癌细胞的生物探针Au NPs@4-MBA@PDA@aHER-2和Au NPs@4-MPY@PDA@aHER-2。SERS性能测试表明,Au NPs能够在低至2 × 10-9 mol/L的浓度下检测和痕量分子。两种生物探针具有良好的光谱稳定性,相对标准偏差(RSD)为9.58%。此外,通过构建具有显著成分分析-线性判别分析(PCA-LDA)的两种生物探针的“交响SERS谱”,区分白细胞(wbc)和两种乳腺癌细胞亚型(SK-BR-3和MDA-MB-231)的分类准确率高达97.33%。机器学习与SERS检测的结合为乳腺癌的早期诊断和个性化治疗提供了新的技术途径。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Nano Biomedicine and Engineering
Nano Biomedicine and Engineering Engineering-Biomedical Engineering
CiteScore
3.00
自引率
0.00%
发文量
9
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书